Canadian Rheumatology Association updates information on ocular toxicity monitoring and provides reassurance on cardiac safety at usual rheumatologic therapeutic doses.
Multicentre trial shows semaglutide reduces body weight, knee pain and analgesic use, and improves physical function in patients with obesity and knee osteoarthritis pain.